Addressing pathogens that compromise ocular health remains a critical component of global eye care. Infectious eye diseases span bacterial, viral, fungal, and parasitic origins, often with rapid onset and potential for lasting visual impairment. Early detection and tailored antimicrobial therapy are vital in cases such as herpetic keratitis, fungal endophthalmitis, and Acanthamoeba infections. Molecular diagnostics and culture techniques continue to improve identification of rare pathogens. In high-risk areas, public health initiatives focus on preventing trachoma and onchocerciasis through antibiotics and vector control programs. Immunocompromised individuals require vigilant monitoring, as opportunistic infections can progress swiftly. Cross-disciplinary collaboration with infectious disease specialists and microbiologists enhances treatment efficacy. Increasing antimicrobial resistance is pushing researchers to develop novel therapeutics and vaccines, ensuring this evolving threat remains manageable in clinical settings.







Title : Lenadogene nolparvovec gene therapy in leber hereditary optic neuropathy
Magali Taiel, GenSight Biologics, France
Title : Stereotactic radiotherapy for wet age-related macular degeneration: year 4 results of a randomised, double-masked, sham-controlled trial
Tim Jackson, King’s College London, United Kingdom